Lymphatic Diseases: Clinical Trials

12,838 trials for Lymphatic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5841 completed, 1838 recruiting, 1676 unknown, 1416 terminated. 5166 Phase 2, 3729 Phase 1, 1663 Not applicable, 1103 Phase 3, 284 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 25166Completed 2291, Recruiting 725, Terminated 709, Unknown 553, Active not recruiting 441, Withdrawn 215, Not yet recruiting 198, Suspended 21, Enrolling by invitation 13
Phase 13729Completed 1702, Terminated 586, Recruiting 479, Unknown 361, Active not recruiting 285, Withdrawn 189, Not yet recruiting 96, Suspended 23, Enrolling by invitation 8
Not applicable1663Completed 760, Unknown 282, Recruiting 266, Terminated 108, Not yet recruiting 89, Active not recruiting 86, Withdrawn 48, Enrolling by invitation 18, Suspended 6
Phase 31103Completed 523, Unknown 167, Recruiting 145, Terminated 104, Active not recruiting 97, Not yet recruiting 35, Withdrawn 27, Enrolling by invitation 3, Suspended 2
Phase 4284Completed 131, Unknown 70, Recruiting 31, Terminated 19, Not yet recruiting 11, Withdrawn 11, Active not recruiting 9, Enrolling by invitation 2
Early Phase 1211Unknown 51, Recruiting 43, Completed 42, Terminated 28, Not yet recruiting 23, Active not recruiting 13, Withdrawn 7, Suspended 4

Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
FLASH Pilot Phase 1 Safety Study
IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma
Not applicableNot yet recruitingLesley A. Jarvis102029-10-312026-11-16
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Phase 3Not yet recruitingAmgen5602028-06-302026-09-15
Pyronaridine in Acute Myeloid Leukemia (AML)
Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 2SuspendedArmaceutica, Inc.2002028-02-212026-10-19
Family-Focused Study to Support Medication for Opioid Use Disorder
FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate
Not applicableNot yet recruitingUniversity of Wisconsin, Madison3382027-08-312026-07-07
Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2Not yet recruitingCity of Hope Medical Center442027-08-042026-09-10
Astragalus for Symptomatic Alleviation in High-grade Lymphoma
Astragalus, Placebo - High-grade Lymphoma
Phase 3Not yet recruitingBnai Zion Medical Center602027-08-012026-09-30
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)2712027-07-272026-11-17
Determining the Safety of CAR T-Cell Therapy for Lymphoma
Chimeric Antigen Receptor (CAR)-positive T- cells, Fludarabine, Cyclophosphamide - Lymphoma, B-Cell, Non Hodgkin Lymphoma
Phase 1Not yet recruitingUniversity of Chicago362027-07-132026-11-19
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 1RecruitingNational Cancer Institute (NCI)152027-07-052026-11-05
VR-PAT and fNIRS to Identify CNS Biomarkers of Pain
VR-PAT - Acute Pain, Pediatric ALL
Not applicableNot yet recruitingNationwide Children's Hospital42027-07-012026-09-09
CAR-T Immunotherapy Targeting CD19- ALL
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002027-07-012026-11-02
Universal 4SCAR7U Targeting CD7-positive Malignancies
Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-11-02
Multi-CAR-T Cells Targeting B Cell Lymphomas
4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL)
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute112027-06-012026-11-02
Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome
Biospecimen Collection, Computed Tomography, Cosibelimab - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome
Phase 1Not yet recruitingCity of Hope Medical Center142027-05-162026-11-09
Early Intervention
Juzo Compression Sleeve and Glove, Compression Sleeve Sensor - Breast Cancer, Breast Cancer Treatment Related Lymphedema
Not applicableNot yet recruitingMassachusetts General Hospital402027-05-012026-07-13
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL
Phase 2Not yet recruitingAbelZeta Inc.552027-05-012026-10-15
Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma
golcadomide, Obinutuzumab, Polatuzumab - Multi Center, Phase 2
Phase 2Not yet recruitingM.D. Anderson Cancer Center602027-04-292026-11-05
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 1RecruitingCity of Hope Medical Center162027-04-172026-11-13
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.
CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies
Phase 1Not yet recruitingGUSTAVO SALGUERO122027-04-012026-10-20
Molecular and Cellular Characterization of MALT Lymphoma
MALT Lymphoma
Not yet recruitingInternational Extranodal Lymphoma Study Group (IELSG)4002027-04-012026-11-12

Showing 20 of 12838. Sign in to see all of them.

Narrower conditions

Lymphoma (3020)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2524)  ·  Lymphoma, Non-Hodgkin (2289)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2020)  ·  Lymphoma, Follicular (1877)  ·  Lymphoma, Large B-Cell, Diffuse (1833)  ·  Leukemia (1371)  ·  Hodgkin Disease (1302)  ·  Lymphoma, Mantle-Cell (1214)  ·  Leukemia, Myeloid, Acute (1018)  ·  Burkitt Lymphoma (978)  ·  Multiple Myeloma (895)  ·  Recurrence (882)  ·  Lymphoma, B-Cell, Marginal Zone (867)  ·  Lymphoma, B-Cell (782)

Broader conditions

Hemic and Lymphatic Diseases (12836)  ·  Immune System Diseases (11547)  ·  Lymphoproliferative Disorders (11382)  ·  Neoplasms by Histologic Type (11288)  ·  Immunoproliferative Disorders (11157)  ·  Neoplasms (11013)  ·  Hematologic Diseases (5454)  ·  Lymphoma (5282)  ·  Leukemia, Lymphoid (4258)  ·  Lymphoma, Non-Hodgkin (4050)  ·  Pathological Conditions, Signs and Symptoms (3934)  ·  Pathologic Processes (3676)  ·  Leukemia (3506)  ·  Disease Attributes (3108)

Interventions

Rituximab (1445)  ·  Cyclophosphamide (1367)  ·  Vincristine (681)  ·  Doxorubicin (603)  ·  Prednisone (550)  ·  Etoposide (543)  ·  Cytarabine (516)  ·  fludarabine (491)  ·  Methotrexate (464)  ·  Dexamethasone (430)  ·  fludarabine phosphate (412)  ·  Lenalidomide (367)  ·  Filgrastim (355)  ·  Bendamustine Hydrochloride (289)  ·  venetoclax (278)

Sponsors

National Cancer Institute (NCI) (567)  ·  M.D. Anderson Cancer Center (421)  ·  Memorial Sloan Kettering Cancer Center (229)  ·  Fred Hutchinson Cancer Center (155)  ·  City of Hope Medical Center (141)  ·  Hoffmann-La Roche (126)  ·  Novartis Pharmaceuticals (117)  ·  Children's Oncology Group (114)  ·  St. Jude Children's Research Hospital (114)  ·  Dana-Farber Cancer Institute (112)  ·  Ruijin Hospital (98)  ·  Mayo Clinic (93)  ·  Assistance Publique - Hôpitaux de Paris (87)  ·  Institute of Hematology & Blood Diseases Hospital, China (85)  ·  Celgene (81)

Countries

United States (6608)  ·  China (1771)  ·  France (1160)  ·  Italy (974)  ·  United Kingdom (827)  ·  Germany (786)  ·  Canada (785)  ·  Spain (756)  ·  Australia (592)  ·  South Korea (452)  ·  Belgium (440)  ·  Poland (396)  ·  Netherlands (384)  ·  Denmark (317)  ·  Japan (301)

Results publications

PMID 34515338, PMID 41671463, PMID 35622074, PMID 40135712, PMID 32632956, PMID 32499241, PMID 34398557, PMID 31401903, PMID 40550489, PMID 38502198, PMID 39319495, PMID 39563886, PMID 26373676, PMID 37505794, PMID 38620092, PMID 23524640, PMID 27209293, PMID 27282998, PMID 31050355, PMID 33242441, PMID 34393061, PMID 39121442, PMID 40802906, PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 23065508, PMID 23834234, PMID 29358183, PMID 30125215, PMID 31196847, PMID 32816215, PMID 34048072, PMID 35787017, PMID 41429239, PMID 17284531, PMID 18596230, PMID 19238148, PMID 26182309, PMID 28054442, PMID 28751558, PMID 31023700, PMID 32770353, PMID 33288485, PMID 33883258, PMID 34608724, PMID 34780125, PMID 34865212

NIH funding

2023 (103), P30CA033572 (103), P30CA015704 (83), 2015 (64), 2016 (60), 2017 (57), 2018 (57), U10CA032102 (50), 2014 (49), 2009 (45), U10CA180820 (45), P30CA016672 (44), U10CA098543 (43), P30CA015083 (41), U10CA031946 (40)